Every baby born in England is offered a small blood test in the first week of life. A few drops of blood from a heel prick are collected on a card and sent for laboratory analysis. It is done quickly, causes brief discomfort, and screens for conditions that are rare but serious enough, and treatable enough early, that testing every baby is justified.
Understanding what the test covers and why each condition is included helps parents make an informed decision about whether to accept it, and to understand what a positive result, which is uncommon, actually means.
Healthbooq (healthbooq.com) covers newborn health and screening in the first weeks of life.
When and How It Is Done
The test is offered at five days of age. The midwife or health visitor makes a small heel prick and collects four or five drops of blood on a special absorbent card. The card is labelled with the baby's details and sent to a regional laboratory for analysis.
The timing matters. For some of the conditions tested, a very early sample (before the baby has had several feeds) will not give an accurate result. Five days allows enough time for the tested substances to reach detectable levels.
Feeding beforehand is fine. Breastfeeding or offering a dummy during the test reduces the pain response, and parents can ask for this.
The result is usually received by four to six weeks. In most cases parents hear nothing because the result is normal and information is recorded in the baby's notes. If there is an abnormal result, the family will be contacted directly by the screening team or their GP within a few days of the laboratory result.
What Is Tested
Nine conditions are currently tested in the NHS England newborn blood spot programme:
Phenylketonuria (PKU) is an inherited disorder of amino acid metabolism. Babies cannot break down phenylalanine, which builds up and causes severe intellectual disability if untreated. Detected at birth, it is treated with a strict phenylalanine-restricted diet. The first child with PKU to be screened at birth in the UK and treated from infancy had normal intellectual development; those born before screening programmes were established often did not.
Congenital hypothyroidism is a deficiency of thyroid hormone from birth, caused by an absent, underdeveloped, or non-functioning thyroid gland. Untreated, it causes growth failure and intellectual disability. Detected early and treated with daily thyroxine tablets, affected children develop completely normally.
Sickle cell disease is a genetic condition affecting haemoglobin that causes episodes of severe pain, anaemia, and increased susceptibility to serious bacterial infection. Early detection allows preventive penicillin to be started before the age of three months, when the risk of life-threatening pneumococcal infection is highest. This intervention alone dramatically reduces early mortality.
Cystic fibrosis (CF) affects the lungs and digestive system. Early diagnosis allows specialist CF centre care to begin before the child has become unwell, significantly improving lung outcomes.
MCADD (medium chain acyl-CoA dehydrogenase deficiency) is a metabolic condition that prevents the body from using fat for energy properly during fasting. Without diagnosis, an ordinary illness causing reduced feeding can be catastrophic. With the diagnosis and parental education about avoiding fasting, the condition is manageable.
Maple syrup urine disease, isovaleric acidaemia, glutaric aciduria type 1, homocystinuria, and other metabolic conditions are also included in the nine, each on the same basis: early treatment prevents serious harm.
Understanding a Positive or Borderline Result
Most positive screening results are not definitive diagnoses: they are indications that further testing is needed. This is by design. Screening tests are designed to be sensitive (not miss cases), which means some positive results turn out to be false positives on further testing.
Receiving a call about an abnormal blood spot result is frightening. It is worth knowing that further confirmatory testing is the next step and that the screening result alone is not a diagnosis. Families are contacted quickly and the further testing happens promptly.
For some conditions (particularly sickle cell trait rather than sickle cell disease), the result reflects carrier status rather than the condition itself. Carriers are generally healthy. This result has implications for family planning and genetic counselling.
Decline and Information
The test is offered, not mandatory. Parents can decline. The vast majority accept it. Declining should be an informed decision, and the midwife or health visitor can answer questions about individual conditions.
Results and any follow-up information become part of the baby's health records.
Key Takeaways
The newborn blood spot test, often called the heel prick test, screens all newborns in England for nine rare but serious conditions, including PKU, congenital hypothyroidism, sickle cell disease, cystic fibrosis, and MCADD. The test is done at five days of age and is offered to all babies. Conditions screened for were chosen because they have effective treatment that prevents or reduces serious harm when started early, but that cannot be identified clinically before serious damage occurs. Most results are normal. When a condition is detected, treatment can begin before the baby has shown any symptoms, dramatically improving outcomes.
